What's breaking now, across thousands of outlets.
Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have “bigger fish to fry” than drug pricing, analysts said.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
CVS Pharmacy will be separate from CVS Health, housing major insurer Aetna and benefits manager Caremark CVS Health, the largest US healthcare conglomerate valued at $117bn, has announced its plans…
CVS Pharmacy will be separate from CVS Health, housing major insurer Aetna and benefits manager Caremark CVS Health, the largest US healthcare conglomerate valued at $117bn, has announced its plans…
Over 57 million people worldwide are living with dementia, with nearly 10 million new cases diagnosed each year, and scientists now say that people living in certain climatic conditions are at a…
In the months leading up to the Treasury Department's release of draft rules that would limit US investment in Chinese biopharma, the industry's view of China was already in a downward sentiment ...
CVS Health is splitting into two publicly traded companies as the healthcare giant fights rising costs, retail competition, regulatory scrutiny and other pressures.
In a recent Yale-led clinical trial, a new type of prostate cancer drug showed promising results in reducing tumor activity and pain for patients with metastatic prostate cancer.
